TRGM OTC
Targeted Medical Pharma, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -90.0%
1Y: -90.0%
3Y: -95.0%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$5M
-26.0% ▼
5Y CAGR: -7.1%
Gross Profit
$3M
-35.3% ▼
5Y CAGR: -8.9%
Operating Income
-$2M
+22.3% ▲
Net Income
-$3M
+21.9% ▲
EPS (Diluted)
$-0.11
+26.7% ▲
EBITDA
-$2M
+24.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 |
|---|---|---|---|---|---|
| Revenue | $9M | $7M | $10M | $7M | $5M |
| YoY Growth | +15.6% | -17.2% | +31.0% | -25.6% | -26.0% |
| Cost of Revenue | $3M | $3M | $3M | $2M | $2M |
| Gross Profit | $6M | $4M | $7M | $5M | $3M |
| Gross Margin | 68.7% | 56.1% | 68.7% | 68.8% | 60.2% |
| R&D Expenses | $163K | $134K | $229K | $158K | $12K |
| SG&A Expenses | $12M | $10M | $10M | $7M | $5M |
| Operating Expenses | $12M | $10M | $10M | $8M | $5M |
| Operating Income | -$6M | -$6M | -$4M | -$3M | -$2M |
| Operating Margin | -65.6% | -84.1% | -40.2% | -36.7% | -38.6% |
| Interest Expense | $876K | $2M | $0 | $1M | $1M |
| Income Before Tax | -$7M | -$13M | -$4M | -$4M | -$3M |
| Tax Expense | -$2M | -$3M | $6M | $66K | $0 |
| Net Income | -$4M | -$10M | -$9M | -$4M | -$3M |
| Net Margin | -47.4% | -131.4% | -97.7% | -54.8% | -57.9% |
| EPS (Diluted) | $-0.19 | $-0.43 | $-0.39 | $-0.15 | $-0.11 |
| EBITDA | -$5M | -$10M | -$3M | -$2M | -$2M |
| Shares Outstanding | 22M | 22M | 24M | 26M | 27M |